Study on rare kidney diseases' impact on kidney failure using data from the UK National Registry of Rare Kidney Diseases (RaDaR) cohort.
Chronic kidney disease (CKD) is a prevalent condition affecting a significant portion of the UK population, especially among the elderly. However, individuals with rare kidney diseases, though accounting for only 5-10% of CKD cases, make up more than 25% of patients requiring kidney replacement therapy. The National Registry of Rare Kidney Diseases (RaDaR) was established to collect longitudinal data on patients with these conditions to study disease progression and outcomes such as death and kidney failure.
A cohort of 27,285 participants with 28 types of rare kidney diseases was recruited from 108 UK renal care facilities. The study found that RaDaR participants had a significantly higher 5-year cumulative incidence of kidney failure compared to 2.81 million UK patients with all-cause CKD but showed better survival rates. The median age at kidney failure, age at death, time from diagnosis to various estimated glomerular filtration rate (eGFR) thresholds, and the therapeutic trial window varied significantly among different rare diseases.
The findings indicated that patients with rare kidney diseases exhibit a different disease trajectory compared to the general population with CKD, with a higher risk of kidney failure but better survival rates. Addressing the unmet therapeutic needs for these patients could potentially reduce the demand for long-term kidney replacement therapy. The study was funded by various organizations, including the Medical Research Council, Kidney Research UK, Kidney Care UK, and the Polycystic Kidney Disease Charity.
The research highlighted the importance of precise diagnosis, early specialist referral, and disease-specific treatments in rare kidney diseases to delay progression to kidney failure. The data provided valuable insights into the natural history and outcomes of various rare kidney diseases, emphasizing the need for tailored interventions to protect kidney function and improve long-term prognosis for these patients. The study's comprehensive analysis and large patient population contribute to a better understanding of rare kidney diseases, informing clinical practice, research, and health-care planning.
Source: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(23)02843-X/fulltext
A cohort of 27,285 participants with 28 types of rare kidney diseases was recruited from 108 UK renal care facilities. The study found that RaDaR participants had a significantly higher 5-year cumulative incidence of kidney failure compared to 2.81 million UK patients with all-cause CKD but showed better survival rates. The median age at kidney failure, age at death, time from diagnosis to various estimated glomerular filtration rate (eGFR) thresholds, and the therapeutic trial window varied significantly among different rare diseases.
The findings indicated that patients with rare kidney diseases exhibit a different disease trajectory compared to the general population with CKD, with a higher risk of kidney failure but better survival rates. Addressing the unmet therapeutic needs for these patients could potentially reduce the demand for long-term kidney replacement therapy. The study was funded by various organizations, including the Medical Research Council, Kidney Research UK, Kidney Care UK, and the Polycystic Kidney Disease Charity.
The research highlighted the importance of precise diagnosis, early specialist referral, and disease-specific treatments in rare kidney diseases to delay progression to kidney failure. The data provided valuable insights into the natural history and outcomes of various rare kidney diseases, emphasizing the need for tailored interventions to protect kidney function and improve long-term prognosis for these patients. The study's comprehensive analysis and large patient population contribute to a better understanding of rare kidney diseases, informing clinical practice, research, and health-care planning.
Source: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(23)02843-X/fulltext
Comments
Post a Comment